This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.
The purpose of this research study is to test a new method for determining the stage and prognosis of patients with malignant pleural mesothelioma. Currently, it is not possible to accurately determine cancer stage prior to surgery or another treatment. This new method may allow doctors to better classify cancer stage and give a better estimate for prognosis prior to surgery or another treatment. In this research study, the investigators would like to use biopsied tissue to study certain characteristics that will help test the new method for determining cancer stage and estimating prognosis. In this research study, the investigators are... * Obtaining pleural specimens at the time of routine diagnostic biopsy during the participant's standard treatment. * Storing your biopsied tissue * Studying the tissue to determine if the new method of staging and prognosis is accurate and valid
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
240
molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
Brigham and Women's Hospital
Boston, Massachusetts, United States
RECRUITINGPre-treatment Prognostic Algorithm Validation
The primary objective is to utilize a novel prognostic algorithm to predict the outcome of MPM patients. This algorithm includes 4 different tests: molecular, radiological, and blood based. It will be performed on 240 prospectively-collected samples. A score of 0-4 will be assigned to each patient and the data will be analyzed by a statistician
Time frame: 4 years
Evaluation of Molecular Tests Base on RNA Expression
The secondary objective is to develop new molecular signatures for distinct clusters of mesothelioma samples grouped according to their gene expression. RNA expression data will be compared between one cluster and all the other clusters and using a variety of statistical and bioinformatics tools. Two-hundred sixteen MPM cases with available RNAseq data will be divided into training and test sets to develop and test potential signatures. The signatures that define each cluster with high sensitivity and specificity will then be tested using RTPCR in a cohort of 555 prospective-collected samples.
Time frame: 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.